.
9966 financial statements
* Numbers in millions
Year |
2019 | 2020 | TTM |
|---|---|---|---|
Capitalization * |
7 297 | 12 366 | 6 759 |
EV * |
5 682 | 12 403 | 12 403 |
Stock price ¤ |
13.6 | 13.3 | 7.27 |
Number of shares * |
537 | 930 | 930 |
EPS |
-1,55 | -0,46 | -0,46 |
Revenue * |
0 | 0 | 0 |
Net income * |
-833 | -428 | -428 |
Operating profit * |
-316 | -365 | -365 |
Total liabilities * |
429 | 366 | 366 |
Net debt * |
-1 615 | 37 | 37 |
Total assets * |
2 855 | 2 640 | 2 640 |
Equity * |
2 426 | 2 273 | 2 273 |
Cash and investments * |
2 382 | 2 064 | 2 064 |
Over the past 10 years, the maximum capitalization of Alphamab Oncology is 12 366, the minimum is 7 297. Maximum net income 0, Minimum net income -833. The maximum price of 9966 shares is 13.6, the minimum price is 13.3.
.
9966 valuation
Year |
2019 | 2020 | TTM |
|---|---|---|---|
P/E |
-8,76 | -28,91 | -15,80 |
P/B |
3,01 | 5,44 | 2,97 |
P/S |
0,00 | 0,00 | 0,00 |
E/P |
-11% | -3% | -6% |
P/FCF |
-18,39 | -28,23 | -15,43 |
.
9966 profitability
Year |
2019 | 2020 | TTM |
|---|---|---|---|
ROE |
-34% | -19% | |
ROA |
-29% | -16% | |
ROIC |
-12% | -16% |